Evidence map›Paper›PMID 29435161›Full record

ArticleOncotarget2018

Nonlinear mixed effects dose response modeling in high throughput drug screens: application to melanoma cell line analysis.

Kuan-Fu Ding, Emanuel F Petricoin, Darren Finlay, Hongwei Yin, William P D Hendricks, Chris Sereduk, Jeffrey Kiefer, Aleksandar Sekulic, Patricia M LoRusso, Kristiina Vuori and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Kuan-Fu DingJ. Craig Venter Institute, La Jolla, CA, USA.
Emanuel F PetricoinGeorge Mason University, Fairfax, VA, USA.
Darren FinlaySanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Hongwei YinThe Translational Genomics Research Institute, Phoenix, AZ, USA.
William P D HendricksThe Translational Genomics Research Institute, Phoenix, AZ, USA.
Chris SeredukThe Translational Genomics Research Institute, Phoenix, AZ, USA.
Jeffrey KieferThe Translational Genomics Research Institute, Phoenix, AZ, USA.
Aleksandar SekulicThe Translational Genomics Research Institute, Phoenix, AZ, USA.
Patricia M LoRussoYale University, New Haven, CT, USA.
Kristiina VuoriSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Jeffrey M TrentThe Translational Genomics Research Institute, Phoenix, AZ, USA.
Nicholas J SchorkJ. Craig Venter Institute, La Jolla, CA, USA.
Translational Genomics Research Institute · USYale University · USGeorge Mason University · USSanford Burnham Prebys Medical Discovery Institute · USUniversity of California, San Diego · US

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Systems BiologyU19AG023122 · NIA · TRANSLATIONAL GENOMICS RESEARCH INST · PI NICHOLAS Joseph SCHORK · 2004 to 2026
$102.6M
UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
Deep sequencing studies for cannabis and stimulant dependenceR01DA030976 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI EHLERS, CINDY L, GELERNTER, JOEL · 2010 to 2014
$16.5M
Integrative Resource to Develop Translational Strategies to Promote LongevityU24AG051129 · NIA · CALIFORNIA PACIFIC MED CTR RES INSTITUTE · PI CUMMINGS, STEVEN RON, EVANS, DANIEL SPENCER · 2015 to 2019
$5.3M
The Bipolar Genome StudyR01MH094483 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CRAIG, DAVID W, EDENBERG, HOWARD J · 2012 to 2014
$2.2M
Identifying the Polygenic Basis of the Human Brain and Psychiatric DisordersR01MH100351 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, CHI-HUA · 2013 to 2017
$2.1M
Somatic Mutations in Brain in Alzheimer's DiseaseR21AG045789 · NIA · UNIVERSITY OF CHICAGO · PI FAULKNER, GEOFFREY JOHN, GERSHON, ELLIOT S · 2014 to 2015
$487k
NCATS NIH HHS UL1 TR001442NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA030199NCI NIH HHS P30 CA033572NIA NIH HHS R21 AG045789NIA NIH HHS U19 AG023122NIA NIH HHS U24 AG051129NIDA NIH HHS R01 DA030976NIMH NIH HHS R01 MH094483NIMH NIH HHS R01 MH100351
6 · The paper itself

Abstract

Cancer cell lines are often used in high throughput drug screens (HTS) to explore the relationship between cell line characteristics and responsiveness to different therapies. Many current analysis methods infer relationships by focusing on one aspect of cell line drug-specific dose-response curves (DRCs), the concentration causing 50% inhibition of a phenotypic endpoint (IC

Indexed as

bioinformaticscancerdrug responsehigh throughput drug screennonlinear mixed effect models

Identifiers

PMID29435161
PMCPMC5797032
OpenAlexW2779360820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.